From: The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement
CS group (N = 131) | WW group (N = 894a) | Mean difference | p-valuec | |
---|---|---|---|---|
(mean ± SD) | (mean ± SD) | (MD ± SD) | ||
RIS b | 5.9 ± 3.11 | 5.7 ± 3.67 | 0.17 ± 0.30 | 0.7966 |
SIS d | 7.1 ± 2.71 | 6.7 ± 3.27 | 0.40 ± 0.26 | 0.7 |
n (%N) | n (%N) | OR (95% CI) | ||
Complete radiological improvement: e | 21 (16.03%) | 94 (10.51%) | 1.62 (0.97 - 2.71) | |
Good radiological improvement: f | 64 (48.85%) | 98 (10.96%) | 7.76 (5.19 - 11.59) | |
No radiological improvement: g | 12 (9.16%) | 55 (6.15%) | 1.54 (0.80 - 2.96) | |
Complete subjective improvement: h | 45 (34.35%) | 189 (21.14%) | 1.95 (1.32 - 2.90) | |
Good subjective improvement: i | 66 (50.38%) | 196 (21.92%) | 3.62 (2.48 - 5.27) | |
No subjective improvement: j | 8 (6.11%) | 57 (6.38%) | 0.96 (0.44 - 2.05) |